Oncolytics Biotech (ONCY) Projected to Post Quarterly Earnings on Friday

Oncolytics Biotech (NASDAQ:ONCY) is expected to issue its quarterly earnings data before the market opens on Friday, March 7th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Oncolytics Biotech Trading Up 13.5 %

NASDAQ ONCY opened at $0.74 on Thursday. The company has a market capitalization of $63.09 million, a PE ratio of -2.73 and a beta of 1.18. The business’s 50-day moving average price is $0.80 and its 200 day moving average price is $0.94. Oncolytics Biotech has a twelve month low of $0.60 and a twelve month high of $1.53.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Oncolytics Biotech in a research note on Monday, February 3rd. Finally, Leede Financial cut Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, November 13th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.